Mesenchymal stem cells (MSCs) have long shown promise in regenerative medicine, with the potential to treat everything from heart disease to autoimmune conditions. But for decades, MSC therapies struggled to move beyond early-phase clinical trials and regional approvals. That changed in December 2024 when the U.S. Food and Drug Administration (FDA) approved RYONCIL—and it became […]
View Blog
Access to cutting-edge gene therapy treatments remains a major challenge, particularly in low- and middle-income countries (LMICs). While these therapies hold the potential to cure life-threatening conditions such as hemophilia, HIV, and sickle cell disease, their availability today is generally limited to patients in wealthier nations with advanced medical infrastructure. The Global Gene Therapy Initiative […]
View Blog
In early January 2025, Bridging the Gap panelists George Eastwood and Patrick Hanley visited Washington, D.C., to advocate for increased support and funding for life-saving cell and gene therapies. Insights from our January 2025 Bridging the Gap Webinar During its first year, the Bridging the Gap Webinar Series, sponsored by Azenta Life Sciences and the […]
View Blog
Insights from our December 2024 Bridging the Gap Webinar Groundbreaking advancements in cell and gene therapies offer unprecedented hope for patients battling cancers, autoimmune diseases, and genetic disorders. Yet, transforming academic breakthroughs into therapies ready for patients is a complex and challenging journey. Issues such as scalable manufacturing processes, navigating diverse regulatory frameworks, and expanding […]
View Blog
Part 1 of a three-part series on cryo cold chain management for cell and gene therapies With a projected rate of 10-20 product approvals per year, the global cell and gene therapy (CGT) industry is rapidly evolving. The clinical pipeline delivers a promise to the patient population with unmet medical needs ranging from oncology to […]
View Blog
Recap from the November 2024 Bridging the Gap webinar Pictured in photo: Sickle cell warrior Jimi Olaghere climbed Mt. Kilimanjaro after receiving advanced gene therapy. The incredible potential of gene therapies like CAR-T and CRISPR to cure genetic diseases and cancers marks a new era in medicine, yet most patients still lack access to these life-saving […]
View Blog
In November 2024, Azenta Life Sciences celebrated the one-year anniversary of its “Bridging the Gap” webinar series, an insightful resource in cell and gene therapy (CGT) education, co-sponsored by the Emily Whitehead Foundation. Over the past year, this series has become a resource for industry experts and CGT professionals, offering critical insights and fostering impactful […]
View Blog
Recap from the October 2024 Bridging the Gap webinar In the rapidly advancing world of cell and gene therapy, we are witnessing groundbreaking innovations that have the potential to cure once-incurable diseases like cancer and sickle cell. Yet, as these transformative therapies emerge, a troubling reality persists: access to these life-saving treatments remains limited. Despite […]
View Blog
Recap from the September 2024 Bridging the Gap webinar Access to life-saving cell and gene therapies is one of the most critical challenges facing healthcare today. While these therapies offer remarkable hope for patients battling life-threatening conditions like cancer and rare genetic diseases, the reality is that only a fraction of eligible patients are actually […]
View Blog
Insights from the August 2024 Bridging the Gap Webinar In the evolving landscape of cell and gene therapy, the manufacturing process is a crucial factor in ensuring that innovative treatments, such as CAR T-cell therapies, reach patients effectively. Autologous cell therapies, which involve modifying a patient’s own cells, present unique challenges that require precise coordination […]
View Blog